



### Company Overview

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

### Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

Sep 17 2020, 7:30 AM EDT

### Rigel to Present at Two Upcoming Investor Conferences

Sep 9 2020, 7:30 AM EDT

### Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference

Sep 2 2020, 7:30 AM EDT

### Stock Overview

Symbol	RIGL
Exchange	Nasdaq
Market Cap	383.47m
Last Price	\$2.27
52-Week Range	\$1.23 - \$5.24

09/25/2020 04:00 PM EDT

### Investor Relations

Rigel Pharmaceuticals, Inc.  
David Burke  
Director, Investor Relations &  
Communications  
ir@rigel.com

### Board of Directors

#### Gary A. Lyons

Chairman

#### Raul R. Rodriguez

President and Chief Executive Officer

#### Bradford S. Goodwin

Director

#### Keith A. Katkin

Director

#### Brian Kotzin, M.D.

Director

#### Gregg Lapointe

Director

#### Walter H. Moos, Ph.D.

Director

#### Jane Wasman

Director

---

### Rigel Pharmaceuticals, Inc.

1180 Veterans Blvd  
South San Francisco, CA 94080

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.